Antihistamine Drugs Market

Growing awareness about therapies related to allergies is driving the market growth

Market CAGR for antihistamine drugs is being driven by the rising awareness about therapies related to allergies. The growing incidence of allergic responses and allergies worldwide and increased public knowledge about managing various reactions to allergens are the primary drivers impacting this market. Allergies remedies are projected to become more popular due to changing lifestyles and innovative pharmacological solutions. There is a considerable demand for these medicines, and the number of people is growing. However, patent expiry, the launch of generic forms of drugs, and the treatment of adverse reactions will likely restrain market expansion throughout the projection period.

Allergic rhinitis has grown over the previous three decades, as reported by the American College of Allergy, Asthma, and Immunology—40% of the people in the United States and Europe to inhalant allergens.

Additionally, changes in lifestyle and the launch of innovative medication treatments for managing allergy illnesses are projected to drive market expansion throughout the forecast period. New product releases and FDA permission for over-the-counter switching of prescription-based nasal sprays are expected to provide attractive opportunities to major industry participants. Collaboration with regional and local players is expected to assist businesses in expanding their geographic reach and offering of goods.

Because nasal antihistamines are the most efficient and popular route of administration, the COVID-19 epidemic boosted sales. However, antihistamine sales were hindered to some amount by restricted international borders, supply delivery networks, stock shortages, and lockdown limitations. According to FMI estimates, the COVID-19 industry will rebound in the following years. This is because of the rise in the need for nose sprays and the number of people who rely on this treatment. These trends will continue in the face of healthcare changes, affecting the demand forecast.

For instance, According to WHO's White Book on Allergy 2011-2012, allergic rhinitis impacted 10%-30% of the population, whereas the average lifetime incidence of urticarial disease was above 20%. A high prevalence of allergies and a rise in incidences among youngsters are expected to increase antihistamine consumption throughout the predicted period. Therefore, it is anticipated that demand for Antihistamine Drugs will increase throughout the projection period due to the rising awareness about allergies-related therapies. Thus, driving the Antihistamine Drugs market revenue.

The increasing prevalence of allergic conditions globally drives the demand for antihistamine drugs. With a notable rise in allergies, particularly in urban areas, the Global Antihistamine Drugs Market Industry is experiencing heightened interest. For instance, the World Health Organization indicates that allergic rhinitis affects approximately 10 to 30 percent of the global population. This growing incidence is likely to propel the market, with projections estimating a market value of 0.17 USD Billion in 2024. As awareness of allergy management increases, the demand for effective antihistamines is expected to rise, further stimulating market growth.

The Global Antihistamine Drugs Market Industry is poised for substantial growth, with projections indicating a market value of 0.17 USD Billion in 2024 and an anticipated increase to 0.44 USD Billion by 2035. This growth represents a compound annual growth rate of 8.93 percent from 2025 to 2035. Such projections reflect the increasing demand for antihistamines driven by rising allergy incidences, advancements in drug formulations, and growing consumer awareness. The market's expansion is likely to be supported by ongoing research and development efforts, regulatory support, and the evolving landscape of consumer preferences.

There is a growing awareness of allergies and their management among the global population, which is positively impacting the Global Antihistamine Drugs Market Industry. Educational campaigns and increased access to information have led to better recognition of allergy symptoms and the importance of treatment. As individuals become more informed, they are more likely to seek antihistamine medications for relief. This heightened awareness is expected to contribute to the market's growth trajectory, with estimates suggesting a market value of 0.17 USD Billion in 2024. The proactive approach to allergy management may further enhance the demand for antihistamines.

The trend towards self-medication is becoming increasingly prevalent, particularly in the context of antihistamine drugs. Consumers are more inclined to purchase over-the-counter antihistamines for managing mild allergy symptoms without consulting healthcare professionals. This shift is evident in the Global Antihistamine Drugs Market Industry, where the convenience of access to these medications is driving sales. The market is expected to grow at a compound annual growth rate of 8.93 percent from 2025 to 2035, reflecting the rising consumer confidence in self-treatment options. This trend may lead to a more significant share of the market being attributed to non-prescription antihistamines.

Innovations in drug formulations are significantly influencing the Global Antihistamine Drugs Market Industry. The development of newer antihistamines with improved efficacy and fewer side effects enhances patient compliance and satisfaction. For example, the introduction of long-acting formulations allows for once-daily dosing, which is particularly appealing to patients. These advancements are likely to contribute to the market's expansion, with a projected growth to 0.44 USD Billion by 2035. The continuous evolution of drug delivery systems and formulations may also attract new consumer segments, thereby broadening the market base.

Regulatory bodies are increasingly supporting the development and approval of antihistamine drugs, which is beneficial for the Global Antihistamine Drugs Market Industry. Streamlined approval processes and guidelines for new antihistamine formulations encourage pharmaceutical companies to invest in research and development. This regulatory environment fosters innovation and the introduction of new products into the market. As a result, the market is projected to grow significantly, reaching 0.44 USD Billion by 2035. The supportive regulatory framework may also enhance competition among manufacturers, leading to a wider variety of antihistamine options for consumers.

By region, the research provides market insights into North America, Europe, Asia-Pacific, and the Rest of the World. The North American Antihistamine Drugs market will dominate this market, owing to the increased incidence of allergic rhinitis and the increasing need for evaluating and managing allergic illnesses.

Further, the major countries studied in the market report are the US, Canada, German, France, the UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.

Figure 2: Antihistamine Drugs Market Share by Region 2022 (USD Billion) 

Source: Secondary Research, Primary Research, Market Research Future Database, and Analyst Review

Europe region’s Antihistamine Drugs market accounts for the second-highest market share. Per the European Academy of Allergies and Clinical Immunology (EAACI), allergies will impact over fifty percent of all Europeans in the next years, boosting the overall market. Further, the German Antihistamine Drugs market holds the largest market share, and the UK Antihistamine Drugs market is anticipated to grow and expand steadily in the European region during the projected timeframe.

The Asia-Pacific Antihistamine Drugs Market is expected to grow significantly during the projected timeframe. This is due to increased demand for pharmaceuticals for treating allergies and skin problems. Moreover, China’s Antihistamine Drugs market dominates the market share, and the Indian Antihistamine Drugs market is anticipated to grow rapidly in the Asia-Pacific region during the projected timeframe.

Leading market players invested heavily in research and development (R&D) to scale up their manufacturing units and product lines, which will help the Antihistamine Drugs market grow worldwide. Market participants are also undertaking various organic or inorganic strategic approaches to strengthen and expand their footprint, with important market developments including new product portfolios, contractual deals, mergers and acquisitions, capital expenditure, higher investments, and strategic alliances with other organizations. Businesses are also coming up with marketing strategies such as digital marketing, social media influencing, and content marketing to increase their scope of profit earnings.

The Antihistamine Drugs industry must offer cost-effective and sustainable options to survive in a dynamic market.

Manufacturing locally to minimize operational expenses and offer aftermarket services to customers is one of the key business strategies organizations use in the Antihistamine Drugs industry to benefit customers and capture untapped market share and revenue. The Antihistamine Drugs industry has recently offered significant advantages to the medicine and service industry. Moreover, more industry participants are utilizing and adopting cutting-edge technology has grown substantially.

Major players in the Antihistamine Drugs market, including Johnson & Johnson Consumer Inc. (U.S.), Sanofi (France), Bayer AG (Germany), Pfizer (U.S.), CVS pharmacy (U.S.), Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc. (U.S.), and Prestige Brands Holdings, Inc. (U.S.), are attempting to expand market share and demand by investing in research and development (R&D) operations to produce sustainable and affordable solutions.

Bayer AG is a German international pharma and biotech corporation, one of the world's leading pharma corporations. It was created in 1863 by chemical merchant Friedrich Bayer and dye firm owner Johann Friedrich Wescott. The company’s headquarters are in Leverkusen, Germany. It develops, manufactures, and distributes goods in medical treatment, dietary habits, and technologically advanced materials. Pharmaceuticals, Crop Science, Consumer Health, Animal Health, and Covestro are its business segments. The Pharmaceuticals division develops, manufactures, and markets prescription drugs for cardiac and women's medical care; specialty therapies in cancer, hematology, and ophthalmology; and medical imaging devices and contrast agents.

The FDA authorized Bayer AG's Astepro to treat periodic and chronic allergies for non-prescription usage beginning in June 2021 via a temporary to non-prescription transfer. This FDA clearance has given people access to a secure, efficient nostril antihistamine without needing a healthcare practitioner.

Glenmark Pharma is a prominent creative pharmaceutical firm dedicated to improving people's lives worldwide. Gracias Saldanha created it in 1977, and it has its headquarters in Mumbai, India. They aim to uncover novel opportunities and improve the well-being of patients worldwide by creating remedies for medical gaps. They have a robust pipeline of new compounds in various stages of discovery aimed at lung disease, cancer, and skincare. Glenmark Pharma is developing cutting-edge treatments for an emerging world. Glenmark has almost 6000 employees spread throughout 80 countries, including 12 production facilities.

Glenmark Pharma will introduce Ryaltris, a novel spray for the nose, in India in May 2021. Glenmark is an innovator in the pulmonary area, having been the first to launch labeled versions cheaply in India.